Toll Free: 1-888-928-9744

Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2017

Published: Aug, 2017 | Pages: 83 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2017, provides an overview of the Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline landscape.

Alpha-antitrypsin deficiency is an inherited disease that occurs due to lack of alpha-1 antitrypsin (AAT), a protein that protects the lungs. Symptoms include shortness of breath and wheezing, lung infections, rapid heartbeat, weight loss and vision problems. Predisposing factors include smoking, exposure to dust, chemical fumes and infections. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Alpha- Antitrypsin Deficiency (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Alpha- Antitrypsin Deficiency and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 2, 9 and 5 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Alpha- Antitrypsin Deficiency (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Alpha- Antitrypsin Deficiency (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Alpha- Antitrypsin Deficiency (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Alpha- Antitrypsin Deficiency (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Alpha- Antitrypsin Deficiency (Genetic Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Alpha- Antitrypsin Deficiency (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Alpha- Antitrypsin Deficiency - Overview 6 Alpha- Antitrypsin Deficiency - Therapeutics Development 7 Pipeline Overview 7 Pipeline by Companies 8 Pipeline by Universities/Institutes 10 Products under Development by Companies 11 Products under Development by Universities/Institutes 13 Alpha- Antitrypsin Deficiency - Therapeutics Assessment 14 Assessment by Target 14 Assessment by Mechanism of Action 16 Assessment by Route of Administration 18 Assessment by Molecule Type 20 Alpha- Antitrypsin Deficiency - Companies Involved in Therapeutics Development 22 Adverum Biotechnologies Inc 22 Alnylam Pharmaceuticals Inc 22 Applied Genetic Technologies Corp 23 Arrowhead Pharmaceuticals Inc 23 Carolus Therapeutics Inc 24 Cevec Pharmaceuticals GmbH 24 Editas Medicine Inc 25 Grifols SA 25 Inhibrx LP 26 Intellia Therapeutics Inc 26 International Stem Cell Corp 27 Kamada Ltd 27 OncBioMune Pharmaceuticals Inc 28 Polyphor Ltd 28 ProMetic Life Sciences Inc 29 rEVO Biologics Inc 29 Z Factor Ltd 30 Alpha- Antitrypsin Deficiency - Drug Profiles 31 ADVM-043 - Drug Profile 31 AGTC-0106 - Drug Profile 33 ALN-AAT - Drug Profile 35 ALNAAT-02 - Drug Profile 38 alpha-1 proteinase inhibitor (human) - Drug Profile 39 alpha-1 proteinase inhibitor (human) second generation - Drug Profile 40 alpha-1 proteinase inhibitor (recombinant) - Drug Profile 44 ARC-AAT - Drug Profile 46 ARO-AAT - Drug Profile 50 CT-2009 - Drug Profile 51 Drug for Chronic Obstructive Pulmonary Disease and Alpha-1 Antitrypsin Deficiency - Drug Profile 52 Gene Therapy for Alpha-1 Antitrypsin Deficiency - Drug Profile 53 Oligonucleotides to Activate Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency - Drug Profile 54 Oligonucleotides to Inhibit Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency - Drug Profile 55 POL-6014 - Drug Profile 56 rAAV2-CB-hAAT - Drug Profile 58 Recombinant Human Alpha-1 Antitrypsin - Drug Profile 59 Recombinant Human Alpha-1 Antitrypsin Replacement for Alpha-Antitrypsin Deficiency - Drug Profile 60 Recombinant Protein for Alpha-1 Antitrypsin Deficiency - Drug Profile 61 Small Molecules for Alpha-1 Antitrypsin Deficiency - Drug Profile 62 Small Molecules to Activate SERPINA1 for Alpha-1 Antitrypsin Deficiency - Drug Profile 63 Small Molecules to Inhibit Alpha-1 Antitrypsin Polymerization for Alpha-1 Antitrypsin Deficiency - Drug Profile 64 Stem Cell Therapy for Alpha-Antitrypsin Deficiency, Crigler-Najjar Syndrome and Liver Cirrhosis - Drug Profile 65 Alpha- Antitrypsin Deficiency - Dormant Projects 66 Alpha- Antitrypsin Deficiency - Discontinued Products 67 Alpha- Antitrypsin Deficiency - Product Development Milestones 68 Featured News & Press Releases 68 Appendix 80 Methodology 80 Coverage 80 Secondary Research 80 Primary Research 80 Expert Panel Validation 80 Contact Us 80 Disclaimer 81
List of Tables
Number of Products under Development for Alpha- Antitrypsin Deficiency, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Alpha- Antitrypsin Deficiency - Pipeline by Adverum Biotechnologies Inc, H2 2017 Alpha- Antitrypsin Deficiency - Pipeline by Alnylam Pharmaceuticals Inc, H2 2017 Alpha- Antitrypsin Deficiency - Pipeline by Applied Genetic Technologies Corp, H2 2017 Alpha- Antitrypsin Deficiency - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2017 Alpha- Antitrypsin Deficiency - Pipeline by Carolus Therapeutics Inc, H2 2017 Alpha- Antitrypsin Deficiency - Pipeline by Cevec Pharmaceuticals GmbH, H2 2017 Alpha- Antitrypsin Deficiency - Pipeline by Editas Medicine Inc, H2 2017 Alpha- Antitrypsin Deficiency - Pipeline by Grifols SA, H2 2017 Alpha- Antitrypsin Deficiency - Pipeline by Inhibrx LP, H2 2017 Alpha- Antitrypsin Deficiency - Pipeline by Intellia Therapeutics Inc, H2 2017 Alpha- Antitrypsin Deficiency - Pipeline by International Stem Cell Corp, H2 2017 Alpha- Antitrypsin Deficiency - Pipeline by Kamada Ltd, H2 2017 Alpha- Antitrypsin Deficiency - Pipeline by OncBioMune Pharmaceuticals Inc, H2 2017 Alpha- Antitrypsin Deficiency - Pipeline by Polyphor Ltd, H2 2017 Alpha- Antitrypsin Deficiency - Pipeline by ProMetic Life Sciences Inc, H2 2017 Alpha- Antitrypsin Deficiency - Pipeline by rEVO Biologics Inc, H2 2017 Alpha- Antitrypsin Deficiency - Pipeline by Z Factor Ltd, H2 2017 Alpha- Antitrypsin Deficiency - Dormant Projects, H2 2017 Alpha- Antitrypsin Deficiency - Discontinued Products, H2 2017



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify